BRNS
Barinthus Biotherapeutics
BRNS
BRNS
16 hedge funds and large institutions have $29.5M invested in Barinthus Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Holders
16
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$46K | |
| 2 | +$17.8K | |
| 3 | +$3K | |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$185 |
Top Sellers
| 1 | -$276K | |
| 2 | -$38.9K | |
| 3 | -$30.6K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.79K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$68 |